Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Results from a Phase 1b Clinical Trial of SMT C1100
Jonathon M. Tinsley(Mary Lyon Centre at MRC Harwell), Kelvin J.A. Davies(University of Southern California), Imelda Hughes(Manchester University NHS Foundation Trust), F. Muntoni(University College London), Helen Roper(Heart of England NHS Foundation Trust), Gary Layton(University of Geneva), R. Ricotti(University College London), Bina Tejura(Summit (United Kingdom)), Stefan Spinty(Alder Hey Children's NHS Foundation Trust)
Cited by 0
Related Papers
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
Mutations in the skeletal muscle α-actin gene in patients with actin myopathy and nemaline myopathy
|Nature Genetics|1999|401
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
|Circulation|2011|375
Degradation of Oxidized Proteins in K562 Human Hematopoietic Cells by Proteasome
|Journal of Biological Chemistry|1996|327
Nrf2-dependent Induction of Proteasome and Pa28αβ Regulator Are Required for Adaptation to Oxidative Stress
|Journal of Biological Chemistry|2012|273